• 한국환경보건학회지
• /
• 제41권6호
• /
• pp.405-411
• /
• 2015

Objectives: The purpose of this study is to evaluate the optimum conditions for oral mucosal irritation testing using the buccal pouch of hamsters. Methods: Test materials were applied to the buccal pouch of seven-week old male Syrian hamsters (SLC, Japan) four times at one-hour intervals and macroscopic changes were examined at 24 hours after final treatment. After sacrifice, the buccal pouches were removed and prepared for histopathological evaluation. In order to set the exposure time, we performed exposure tests of 5, 12, 18 and 23 minutes using sodium lauryl sulfate (SLS) 1% and set the treatment volume from the test results at 2, 3, or 4 ml treatment using SLS 1%, Triton X-100 1% and ethanol. After setting the experimental conditions, seven groups of materials [sodium lauryl sulfate (SLS) (1%), Triton X-100 (1%), hydrogen peroxide (3%), ethanol (100%), chlorhexidine (0.2%, 2%), phosphate buffer saline (PBS)] were assessed. Results: Experimental conditions of material exposure time were fixed as 18 minutes from the exposure tests of 5, 12, 18 or 23 min using sodium lauryl sulfate (SLS) 1%. Treated volume was set as 4 ml per each pouch from the test results of 2, 3, or 4 ml treatments using SLS 1%, Triton X-100 1% and ethanol. The results in terms of irritation degree were in the order of sodium lauryl sulfate (SLS) (1%) > Triton X-100 (1%) ${\fallingdotseq}$ hydrogen peroxide (3%) > ethanol (100%) ${\fallingdotseq}$ chlorhexidine (0.2%, 2%) > phosphate buffer saline (PBS). Conclusion: From this study, suitable conditions for hamster mucosal irritation testing were suggested and this method was verified through materials commonly used on oral mucosal membranes.

• 대한화장품학회지
• /
• 제38권4호
• /
• pp.305-310
• /
• 2012

우리는 평생 동안 하루도 빠짐없이 치약과 같은 구강관리 제품들을 사용한다. 이와 같이 매일 입에 사용되는 제품의 안전성이 담보되어야 함은 매우 중요한 일이다. 이전까지 이루어진 동물시험이나 임상시험에서 치약 내 계면활성제 등에 의한 구강 자극이 유발될 수 있음이 알려져 있다. 하지만, 동물복지를 위하여 유럽 화장품 법안은 화장품과 그에 사용하는 원료에 대한 동물 시험을 금지했다. 그로 인해 여러 분야에서 동물을 대체하거나 동물의 사용을 줄일 수 있는 동물대체 시험법의 개발이 활발하게 이루어지고 있다. 하지만, 현재까지 구강 점막 독성을 측정할 수 있는 방법으로 임상시험과 동물시험이 있었으며, 최근에는 구강 점막 조직 모델이나 구강 세포들을 활용한 방법들이 연구되고 있다. 이번 연구의 목적은 구강관리 제품의 안전성을 확보할 수 있는 동물대체 시험법을 개발하는 것이다. 구강 세포주(YD-38 cell)를 활용해 불용성 물질을 포함한 치약에 대한 시험이 가능하도록 구강 점막 자극 시험법을 개발하였고, 이 시험법으로 이전에 이루어진 동물시험에서 자극유발원으로 알려진 물질에 의한 자극을 구별해낼 수 있었다. 또한, 유아와 어린이 치약의 자극 수준이 일반 성인 치약에 비해 낮음을 증명하였다. 이 결과를 바탕으로 동물을 사용하지 않고 인체에 대한 위해성을 줄일 수 있도록, 구강관리 제품의 구강 점막 자극 수준을 평가할 수 있는 이 시험법이 하나의 새로운 구강 자극 시험 방법으로 사용될 수 있으리라 사료된다.

• Toxicological Research
• /
• 제17권3호
• /
• pp.167-171
• /
• 2001

Oral mucous membrane test using Syrian hamsters was performed to evaluate the reliability as a model system for the assessment of the potentially irritating substances intended for the mucous membranes, and to determine the irritating potential of a new emulsion-type formulated toothpaste. After test substances were implanted into the cheek pouches of hamsters with diluents (20 mg/kg) under pento-barbital sodium anesthesia, we made the comparison in irritation between emulsion-type and dispersion-type of triclosan (TCS) formulations in the range of 0.2% to 0.3%. The emulsion-type formulations using non-ionic surfactant showed less mucosal lesion than other commercial toothpastes with 0.3% TCS, or dispersion-type ones. However, no significant difference in irritation was detected between 0.2% and 0.3% TCS. We report that this hamster cheek pouch method could be a reliable approach for the evaluation slight difference in the irritating potentials of cosmetics and hygiene products intended for the lips or other mucous membranes, and this method showed that the new emulsion-type formulation significantly lowered the TCS-induced toxicity, compared with other commercial toothpastes.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제47권2호
• /
• pp.145-148
• /
• 2021

Minor salivary gland sialolithiasis (MSGS) is a not uncommon oral mucosal disease. Its clinical appearance may mimic a mucocyst or other benign submucosal overgrowth. Stasis of saliva, which accompanies MSGS, usually results in minor salivary gland inflammation, with a chronic sialadenitis appearance. MSGS typically is a painless lesion but can become painful when the salivary gland parenchyma or excretory duct becomes infected, with or without pus. However, misdiagnosis of this condition is rather common, as the clinical appearance is asymptomatic. The most common location is the upper lip, and MSGS affects males and females, with a slight predilection for males. The sialolith causing MSGS may be obvious during surgical excision, as in the case reported. In other cases, sialolith may be absent or fragmented. Differential diagnosis includes mucocele, swelling due to local irritation like fibroma and diapneusia, chronic abscess of the oral mucosa, and neoplasms either benign (lymphangioma, pleiomorphic adenoma) or malignant. Histopathological examination is needed to establish clinical diagnosis.

• Archives of Pharmacal Research
• /
• 제22권1호
• /
• pp.44-47
• /
• 1999

Three 1,2-benzothiazine derivatives were synthesized, and their analgesic / anti-inflammatory efficacy and their effect s of gastric irritation were evaluated. Among the three compounds, 39 exhibited the most potent anlagesic action, but the effect was weaker than that of piroxicam. Nonetheless, the compound showed 4 times more potent analgesic action with less gastric damage than did ibuprofen. These compounds did not show anti-inflammatory effect at an oral dose of 5 mg/kg.

• Archives of Pharmacal Research
• /
• 제20권5호
• /
• pp.414-419
• /
• 1997

Gastrointestinal irritation is the most frequent adverse effect in patients chronically taking nonsteroidal antiinflammatory drugs (NSAIDs) for the treatment of arthritic conditions. Gastroprotective effect of DA-9601, a new antiulcer agent from Artemisiae Herba extract, against NSAID was evaluated in a rat model of arthritis that is similar in many aspects to human rheumatoid arthritis. Daily oral dosing of naproxen (30 mg/kg), one of the most commonly used NSAID, induced apparent gastric lesions as well as a significant decrease in mucosal prostagiandin $E_2;(PGE_2)$ and prostagiandin F_${1{\alpha}}$$(PGF_{1{\alpha}})$ levels. Coadministration of DA-9601 prevents naproxen-induced mucosal injury and depletion of prostaglandins, in a dose-related manner. DA-9601 did not alter the antiinflammatory or analgesic effect of naproxen. The present results suggest that DA-9601 may be useful as a mucoprotectant against NSAIDs in clinical practice.